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Abstract—Studies of submillimeter gels composed of covalently 
cross-linked poly(acrylic acid)-g-poly(ethylene oxide)-b-
poly(propylene oxide)-b-poly(ethylene oxide) (Pluronic-PAA) 
networks are reviewed in light of potential applications of the 
microgels as drug carriers in oral delivery. The microgels are 
capable of volumetric transitions in response to environmental 
stimulae such as pH and temperature.  It is shown that the type of 
Pluronic used in the microgel synthesis changes the structure of 
the resulting microgels, with the more hydrophobic Pluronic 
imparting porosity. Microgels based on Pluronic L92 (L92-PAA-
EGDMA) possess higher ion-exchange capacity than microgels 
based on Pluronic F127 (F127-PAA-EGDMA), albeit the former 
are more hydrophobic. Analogously, more hydrophobic but 
heterogeneous L92-PAA-EGDMA exhibit superior capacity for 
equilibrium loading of hydrophobic drugs such as taxol, 
camptothecin and steroid hormones, as well as higher capacity for 
weakly basic drugs such as doxorubicin, mitomycin C, and 
mitoxantrone.  
 
Index Terms—Anticancer drugs, hydrophobic solutes, oral 
drug delivery, smart microgels 
 
I. INTRODUCTION 
he delivery of drugs currently used in cancer treatment is 
performed mostly through intravenous drug infusions or 
topically [1]. Due to unfavorable pharmacodynamics, the 
infusions need to be performed frequently, exacerbating the 
potential for side effects. Oral treatment with anticancer drugs 
can be preferred as this delivery route is convenient to 
patients, reduces administration costs and facilitates the use of 
more chronic treatment regimens. Thus far, low oral 
bioavailability has usually limited the development of cancer 
treatment by the oral route. We have developed novel 
temperature- and pH-sensitive gel microparticles as feasible 
vehicles for oral delivery of anticancer drugs. The microgels 
consist of covalently cross-linked copolymers of poly(acrylic 
acid) (PAA) and poly(ethylene oxide) (PEO) and 
poly(propylene oxide) (PPO) PEO-PPO-PEO copolymers 
(trademark Pluronic®). The Pluronic-PAA copolymers are 
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obtained via a unique one-step template polymerization of 
acrylic acid in the presence of Pluronic, with a chain transfer 
to the Pluronic [2-5]. The synthesis results in graft-comb 
structures of high molecular weight (above 105 g/mol) and is 
optimized to yield extremely low concentration of toxic 
admixtures, acceptable for medicinal use [2]. The copolymers 
typically consist of about 50 wt% of PAA chains grafted to the 
polyether backbone of the Pluronic copolymer via C-C 
bonding [2-5]. Introduction of divinyl cross-linkers such as 
ethylene glycol dimethacrylate (EGDMA) into the synthetic 
route developed for the Pluronic-PAA enables preparation of 
submillimeter gel microparticles capable of volume phase 
transitions in aqueous solutions [6]. Since these transitions can 
be controlled by changing the quality of aqueous solvent, the 
microgels are termed smart, or intelligent. When swollen, the  
size of microgels (tens of microns) will prohibit their passage 
through gastrointestinal walls. Yet, because of the strong 
mucoadhesive properties of the Pluronic-PAA [7-10], the 
microgels can adhere longer onto the mucosal tissues, thus 
providing potential for sustained release of the loaded drugs by 
diffusion. The Pluronic-PAA have been shown to form 
micelle-like aggregates in aqueous solutions, capable of 
solubilization of hydrophobic compounds [11-15]. These 
considerations motivate the ongoing effort by our group to 
elucidate the drug-microgel interactions. All the drugs chosen 
for our studies (Fig.1) are currently in clinical use in various 
anticancer therapies. Yet, these drugs exhibit vastly different 
physical and chemical properties (Table 1), depending on the 
presence of ionizable groups. Compounds such as mitomycin 
C, doxorubicin, and mitoxantrone are weakly basic and are 
applied in pharmaceutical formulations as hydrochloride salts, 
whereas taxol, camptothecin, and steroid hormones estradiol 
and progesterone are neutral and mostly water-insoluble. As 
described below, we discovered that because of the unique 
polyelectrolyte and aggregate-forming structure of the 
microgels, they are capable of holding large amounts of both 
ionic and hydrophobic drugs.  
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II. EXPERIMENTAL 
A. Materials 
Nonionic polymers Pluronic F127 NF and L92 were 
obtained from BASF Corp. and used without further treatment. 
Acrylic acid (99%, vinyl monomer), ethylene glycol 
dimethacrylate (98%, divinyl cross-linker), dodecane (99+%, 
solvent), and 4,4'-azobis(4-cyanovaleric acid) (75+%, azo 
initiator) were purchased from Aldrich Chemical Co. and used 
as received. Lauroyl peroxide (97%, redox initiator) was 
obtained from Fluka Chemie AG (Switzerland). 
Poly(vinylpyrrolidinone-co-1-hexadecene) (Ganex V-216) 
(dispersion stabilizer) was obtained from International 
Specialty Products (Wayne, NJ). Doxorubicin hydrochloride 
and taxol (paclitaxel), both of 99% purity, were obtained from 
Hande Tech USA (Houston, TX), a subsidiary of Yunnan 
Hande Technological Development Co.(Kunming, P.R.China). 
Mitomycin C, camptothecin, mitoxantrone dihydrochloride, β-
estradiol and progesterone were obtained from Sigma-Aldrich 
Co.  and used as received. All other chemicals, gases and 
organic solvents of the highest purity available were obtained 
from commercial sources. 
 
B. Microgel synthesis 
Synthesis was carried out on a laboratory scale in an 
adiabatic mode. Acrylic acid (40 mL) was partially neutralized 
by addition of 5 M NaOH aqueous solution (0.5 mL). Pluronic 
(24 g) was dissolved in the resulting solution under nitrogen 
and a desired amount of ethylene glycol dimethacrylate 
(EGDMA) was added. The molar ratio of the EGDMA to 
acrylic acid set in the reaction mixture designates the degree of 
cross-linking of the microgels [XL, mol%= 100*(number of 
mols of EGDMA/the number of mols of acrylic acid)]. Lauroyl 
peroxide (100 mg) and 4,4'-azobis(4-cyanovaleric acid) (100 
mg) were dissolved in 2 mL of acrylic acid and added to the 
solution of Pluronic in acrylic acid. The resulting solution was 
deaerated by nitrogen bubbling for 0.5 h and added to a 3-
necked 0.5-mL flask containing 1 wt% solution of Ganex V-
216 in dodecane (200 mL). The flask was vigorously stirred by 
a mechanical stirrer and deaerated by constant nitrogen purge 
from the bottom. Then the flask was heated to 70 oC using an 
oil bath and kept at that temperature under stirring and 
nitrogen purge. After about 1 h, formation of white particles 
was observed on the flask walls. The reaction was continued at 
70 oC for another 3 h. Then the reactor was disassembled, and 
the contents of the reactor were filtered using Whatman filter 
paper (retention size 10 µm). The microgel particles were 
extensively washed by hexane and dried under vacuum.  Dry 
and swollen/lyophilized particles were observed using a 
scanning electron microscope (SEM). 
TABLE I 
PROPERTIES OF DRUGS USED IN THE STUDY 
Drug Molecular 
mass 
LogP Solubility 
parameter 
(MPa1/2) 
Taxol 853.3 4 b 28.7 e 
Camptothecin 348.4 0.87 c 29.2 e 
Progesterone 314.5 3.77 d 17.6 f 
β-Estradiol 272.4 3.86 d 21.1 f 
a Mitomycin C
   
334.1 -0.4 g 30.5 e 
a Mitoxantrone
   
444.2 0.24 c 27.3 e 
a Doxorubicin
   
543.5 1.85 g 27.3 e 
a Data for free bases, and not hydrochloride salts. 
b Niethammer, A., Gaedicke, G., Lode, H.N., Wrasidlo, W. 
Bioconjugate Chem., 2001, 12, 414-420 
c Calculated using ClogP Program (BioByte Corp.) 
d Data from Johnson, M.E., Blankschtein, D., Langer, R. 
J.Pharm.Sci. 1995, 84, 1144; Kamlet, M.J., Doherty, R.M., Carr, 
P.W., Mackay, D., Abraham, M.H., Taft, R. Environ. Sci.Technol. 
1988, 22, 503. 
e Calculated using Molecular Modeling Pro. (version 2.14, 
WindowChem Software, Inc.) 
f Hildebrand parameter data are taken from Michaels, A .S., Wong, 
P.S.L., Pratner, R., Gale, R.M., AIChE J., 1975, 21, 1073 
g Hansch, C., Leo, A. Exploring QSAR, Vols.1-2,  American 
Chemical Society, Washington, DC, 1995 
 
 
 
C. Solute loading 
Water-soluble solutes 
The maximum loading level of doxorubicin, mitoxantrone, 
and mitomycin C into microgels was measured using a 
Millipore Ultrafree-MC Centrifugal Filter Device (Millipore, 
Co.). A microgel was suspended in Tris buffer (5 mM, pH 7.0) 
and 50 mL of the suspension (2 mg gel/mL buffer) were 
equilibrated with 3.0 mM  stock solution of a drug (450 µL) 
for 16 h while shaking. Shaking was performed using a KS10 
orbital shaker (BEA-Enprotech Corp., Hyde Park, MA) in an 
environmental chamber at 37 °C.  After equilibration, the 
microgel particles were filtered off by centrifugation 
(10000xg, 0.5 h) and supernatant was assayed for drug 
concentration. A Shimadzu Model 1600 PC spectrophotometer 
with a temperature-controlled quartz cuvette (path length 1 
cm) was used for electronic absorption measurements. The 
extinction coefficients of doxorubicin (λ=482 nm) and 
mitoxantrone (λ=614 nm) were determined at pH 7.0 to be 
12200 and 22100 M-1 cm-1, respectively. The concentration of 
mitomycin C was assayed by HPLC using a Capcell Pak MF 
Ph-1 (100 x 4.6 mm I.D., particle size 5 µm) column 
(Phenomenex, Torrance, CA). The HPLC was a Hewlett-
Packard 1090 system with an autosampler and a variable 
wavelength UV detector controlled by the HPLC Chemstation 
software (Hewlett-Packard). Deionized water was used as the 
mobile phase (flow rate, 1 mL/min, injection volume, 25 µL), 
and detection was carried out at 365 nm. The typical retention 
time of mitomycin C was 4.88 min. The drug uptake was 
expressed as: 
 U (mmol drug/g gel)=[(Ac-Ar)/Ac]VCs/Mgel, 
where Ac and Ar are the absorbance or HPLC readings in 
the appropriately diluted stock solution and in the system 
equilibrated with microgel, respectively, V=0.5 ml is the total 
volume of the system, Cs=3 µmol/mL is the concentration of 
the stock solution, and Mgel=0.1 mg is the microgel mass. The 
U values were measured in triplicate for each solute and for 
each gel, respectively.  
Hydrophobic solutes 
The loading of the hydrophobic solutes such as taxol, 
camtothecin, and estradiol into microgels was measured by 
equilibrating solute adsorbed onto steel beads with the 1 wt% 
suspension of microgels (pH 7.0). Stainless steel beads (1-3 
mm diameter) were soaked in 10 mM solution of the solute in 
either acetonitrile (taxol), dimethylsulfoxide (camptothecin), 
or absolute ethanol (estradiol, progesterone), following by 
stripping off the solvent under vacuum. The beads were used 
in order to enhance the area of contact between the microgel 
suspension and taxol. The beads were separated into several 
fractions. One fraction was added to a polypropylene vial 
containing the microgel suspension (0.5 mL) and the vial was 
gently shaken in a horizontal position in an environmental 
chamber at 20 or 37 °C.  Then the beads were recovered from 
the suspension by using a magnet. The beads were dried under 
vacuum and placed into an appropriate solvent (0.5 mL), 
where the solute was extracted after shaking overnight. The 
solvent fraction was assayed for the solute concentration using 
HPLC. The control fraction of loaded beads was subjected to 
the extraction without equilibration with the microgel 
suspension. The solute concentrations were measured in 
triplicate using the HPLC system described above. The 
chromatography assay for taxol comprised the use of a Capcell 
Pak C18 UG 120 (150 x 4.6 mm I.D., particle size 3 µm) 
column (Phenomenex), acetonitrile-0.1% phosphoric acid in 
DI water (55:45 v/v, 1.3 mL/min) as a mobile phase, and UV 
detection at 227 nm.  The typical retention time of the taxol 
peak was 3.46 min. For camptothecin assay, a solution of the 
drug in DMSO (50 µL) was injected onto the aforementioned 
C18 column and eluted at 1 mL/min flow rate and 40 oC using 
0.1 M ammonium acetate (pH 5.6) and acetonitrile as mobile 
phase. A linear gradient of 45% to 85% acetonitrile was 
applied, and the UV/vis detection was carried out at 254 and 
370 nm. The retention time of the camptothecin peaks was 7.5-
8.5 min. The peak area was integrated and used to calculate 
camptothecin concentration using standard calibration curves. 
The HPLC assay of estradiol and progesterone solutions in 
ethanol was performed as described previously [15]. 
III. RESULTS AND DISCUSSION 
SEM microgel characterization 
Significant differences were observed in the shape and 
structure of as-prepared L92-PAA-EGDMA and F127-PAA-
EGDMA particles (Fig.2). The majority of the F127-PAA-
EGDMA particles were spherical and contained no observable 
pores. The size distribution was somewhat broad, ranging from 
about 5 to 100 µm. Particle sizing performed in hexane yielded 
effective median diameter of 13 µm and polydispersity of 1.4 
for this type of particles. 
The surface of the spherical F127-PAA-EGDMA particles 
contained a tree-like pattern with submicron depth. The 
formation of characteristic patterns in the droplets caused by 
competition between phase separation and chemical reaction 
has been observed  [16]. In our case, such patterns can be due 
to rapid polymerization of acrylic acid, followed by phase 
separation. Note that while acrylic acid monomer is miscible 
with hydrocarbon where polymerization takes place, the 
resulting PAA and Pluronic-PAA are not. The phase-separated 
microdroplets that still contain monomer on their interface are 
bridged by further polymerization and cross-linking reactions. 
The droplet interface becomes diffuse over time and the 
droplets eventually fuse together. It is believed that the 
differences in the reaction kinetics and phase separation speed 
imparted by the presence of varying fractions of PPO in 
different Pluronics resulted in profound differences in the 
structure of the F127-PAA-EGDMA and L92-PAA-EGDMA 
particles (compare structures in Figs.2). Unlike larger and 
smooth F127-PAA-EGDMA particles, their more hydrophobic 
L92-PAA-EGDMA counterparts consisted of a sponge-like, 
interconnected and fused network of submicron spherical 
particles. The resulting “sponge agglomerates” were rough but 
 
 
spherical and were on average smaller than F127-PAA-
EGDMA particles (particle sizing in hexane yielded effective 
median diameter of 4 µm and polydispersity of 1.5 for L92-
PAA-EGDMA). The observed differences in the structure can 
be traced to the more than 2-fold higher content of PPO in the 
latter systems.  
 
Fig.2. SEM photographs of the F127-PAA-EGDMA and 
L92-PAA-EGDMA “as made” particles. 
 
We have observed previously [3] that the higher content of 
PPO in the template polymerization of acrylic acid on Pluronic 
results in dramatic increase of branching and cross-linking in 
Pluronic-PAA at the same degree of conversion of acrylic 
acid. This is because of much higher propensity of PPO 
(compared to PEO) for the hydrogen abstraction reactions [3]. 
Certainly, this as well as higher tendency of more PPO-rich 
Pluronics to phase separate in organic solvents, can translate 
into the formation of stable microdroplets that get connected at 
the later stages of polymerization (L92-PAA-EGDMA) as 
compared to formation of Pluronic-PAA copolymers in 
relatively large droplets, which become phase separated as a 
whole at later stages of the polymerization (F127-PAA-
EGDMA).  
Upon equilibrium swelling in water, the F127-PAA-
EGDMA microgels expanded but maintained their spherical 
shape (Fig.3). The surface pattern developed into 1-2 µm deep 
“craters” that were not interconnected. We have previously 
reported that the bulk of the F127-PAA-EGDMA microgels 
SEM-imaged using freeze-fracturing technique appears to be 
homogeneous, devoid of any discernible pore structure [6]. In 
the L92-PAA-EGDMA, the gaps between interconnected 
micro- or nanospheres (resulting from polymerized 
microdroplets) widened upon swelling, yielding a well-
developed porous structure with the pores on the order of 100 
nm wide (Fig.3). The submicron spheres themselves did not 
expand significantly in water, presumably because of the high 
PPO content making them hydrophobic. 
 
Fig.3. SEM photographs of the surface of the F127-PAA-
EGDMA (upper photo) and L92-PAA-EGDMA (lower photo) 
microgels equilibrium-swollen at pH 7.0 and lyophilized. 
 
Equilibrium drug uptake 
The equilibrium loading of weakly basic, ionized drugs into 
microgels at 37 oC is shown in Fig.4. As is seen, the uptake by 
porous but more hydrophobic L92-PAA-EGDMA microgels 
L92-PAA-EGDMA
F127-PAA-EGDMA
 
 
was consistently higher than for more hydrophilic F127-PAA-
EGDMA microgels. This corresponded to the differences in 
the total ion-exchange capacity of the microgels measured by 
potentiometric titration to be 6.1 and 7.2 meq/g dry gel for 
F127-PAA-EGDMA and L92-PAA-EGDMA, respectively. 
The ratio of the drug loading into these two types of microgels 
was 0.84-0.91 of the ratio of their respective total ion-
exchange capacities. Hence, the loading of the small basic 
drugs into the microgels is determined by the ion-exchange 
equilibria. 
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Fig.4. Equilibrium uptake of weakly basic anticancer drugs 
into microgels at 37 oC and pH 7.0. 
 
General trends important for drug loading via the ion-
exchange mechanism were studied using the potent 
chemotherapeutic drug doxorubicin (Fig.5). As the degree of 
carboxyl group ionization increases with pH, the ion-exchange 
capacity of the microgels increases, reaching about half of the 
maximum capacity found by titration, indicating that the 
loading of doxorubicin can be limited by the available free 
volume of the network. Notably, the pH-dependencies of the 
equilibrium swelling [6] and doxorubicin loading (Fig.5) 
coincide, demonstrating that the uptake is limited by the 
collapsed microgels. Clearly, such pH-sensitivity to the uptake 
and release of the drug provides advantage for the drug 
delivery, as the microgels can be loaded when swollen and 
unloaded by pH cycling, which is especially important for 
targeted oral delivery, where acidic pH is observed in the 
stomach and neutral pH in the intestine. The uptake of the 
hydrophobic drugs by our microgels is depicted in Fig.6, 
which shows that the more hydrophobic L92-PAA-EGDMA 
possesses a higher capacity for these drugs. Generally, the 
uptake is on the order of µmol/g gel, which is about 1000-fold 
lower than in the case of the bases, which are loaded via ion-
exchange equilibria. Taxol and other hydrophobic drugs are 
solubilized by the hydrophobic PPO domains in the microgels. 
The latter notion is supported by the fact that the equilibrium 
solubility of taxol in water is many times less than the 
equilibrium solubility in 1 wt% microgel suspension [6]. The 
same holds for the other hydrophobic drugs under study. The 
solubilizing capacity of the microgels for taxol and steroid 
hormones is at least equal to that 
of.
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Fig.5. Equilibrium uptake of doxorubicin by F127-PAA-
EGDMA microgels  as a function of pH at 37 oC. 
 
Pluronic-PAA micelles [15]. The characteristic increase in 
the drug loading capacity at higher temperatures (compare 
results at 20 and 37 oC in Fig.6) above critical aggregation 
temperatures provides additional evidence to the suggested 
mechanism of hydrophobic drug solubilization into micelle-
like aggregates within the microgels via entropic interactions. 
The formation of the aggregates within microgel particles due 
to the aggregation of dangling chains of Pluronic has been 
demonstrated in our previous work [6]. The micelles in 
Pluronic-PAA solutions typically have solubilizing capacity 
similar to that in the Pluronic aqueous solutions [15].  A more 
hydrophobic L92-PAA-EGDMA showed a higher uptake for 
all the hydrophobic drugs studied than its more hydrophilic 
counterpart (Fig.6), which is consistent with the 
aforementioned solubilization mechanism. The least 
hydrophobic of the four drugs, camptothecin, showed higher 
uptake by the microgels (see LogP data in Table 1 and Fig.6). 
This can be explained by the fact that the loading of the 
amphiphilic solute can occur both via the solubilization into 
hydrophobic PPO cores of the aggregates and entrapment into 
more hydrophilic core-swollen gel interface [12]. The ability 
of the microgels to effectively load and hold hydrophobic 
drugs, combined with high loading of basic drugs and 
mucoadhesive properties provides unusual possibilities for 
anticancer therapies by oral delivery. 
IV. CONCLUSIONS 
 The study dealt with microgels that consist of loosely cross-
linked poly(acrylic acid) onto which Pluronic F127 (formula 
EO99PO67EO99) or L92 (formula EO8PO52EO8 ) segments are 
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Fig.6. Equilibrium uptake of hydrophobic drugs by 
microgels  at pH 7.0 at 20 and 37 oC. 
 
grafted. The microgels based on more hydrophobic Pluronic 
L92 exhibited highly porous structure, while the F127-PAA-
EGDMA microgels were generally larger and showed smooth, 
homogeneous structure and lower ion-exchange capacity. The 
differences in the microgel structure account for the 
differences in the capacity of the microgels to absorb drugs, 
either weakly basic or hydrophobic. Further collaboration 
between MIT and Singapore will concentrate on mechanistic 
aspects of the drug-microgel interactions and possibly explore 
protein-microgel interactions. It has been shown that Pluronic-
PAA copolymers can  stabilize proteins in aqueous solutions 
because of micellization and polyelectrolyte properties [17]. 
The novel microgels should add to the arsenal of the 
pharmaceutical technology because of capacity to change 
behavior in response to the environmental stimulae, ability to 
hold both hydrophobic and ionic drugs and benign, non-
irritating nature.   
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